Inhibition of mPGES-1 or COX-2 Results in Different Proteomic and Lipidomic Profiles in A549 Lung Cancer Cells

Inhibition of mPGES-1 or COX-2 Results in Different Proteomic and Lipidomic Profiles in A549 Lung Cancer Cells

Pharmacological inhibition of microsomal prostaglandin E synthase (mPGES)-1 for selective reduction in prostaglandin E2 (PGE2) biosynthesis is protective in experimental models of cancer and inflammation. Targeting mPGES-1 is envisioned as a safer alternative to traditional non-steroidal anti-inflam...

Full description

Bibliographic Details
Main Authors: Filip Bergqvist, Elena Ossipova, Helena Idborg, Joan Raouf, Antonio Checa, Karin Englund, Petter Englund, Payam Emami Khoonsari, Kim Kultima, Craig E. Wheelock, Karin Larsson, Marina Korotkova, Per-Johan Jakobsson
Format: Article
Language:English
Published: Frontiers Media S.A. 2019-06-01
Series:Frontiers in Pharmacology
Subjects:
microsomal prostaglandin E synthase-1 inhibitor
prostaglandin E2
cancer
inflammation
cyclooxygenase-2 inhibitor
Online Access:https://www.frontiersin.org/article/10.3389/fphar.2019.00636/full

Internet

https://www.frontiersin.org/article/10.3389/fphar.2019.00636/full

Similar Items